BackHeXun Biosciences , Ltd. Overview

HeXun Biosciences , Ltd. Other Current Assets

Latest other current assets for 6986.TWO: $16M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$16.40M
↓ 7.94% YoYΔ $-1.41M vs prior year quarter

Peer average / median

Loading

HeXun Biosciences , Ltd. Other Current Assets History

Loading

HeXun Biosciences , Ltd. vs. peers: Other Current Assets Comparison

Loading

HeXun Biosciences , Ltd. Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

HeXun Biosciences , Ltd. (6986.TWO) FAQ

As of the most recent data (June 2026), 6986.TWO shows a other current assets of $16M. That compares with $18M in the prior-year period — down 7.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6986.TWO's other current assets is now $16M (was $18M) — a 7.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether HeXun Biosciences , Ltd. is outperforming or lagging.

Tracking 6986.TWO's other current assets over time shows whether HeXun Biosciences , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $18M in the prior-year period — down 7.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has HeXun Biosciences , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $16M) with ownership activity and broader fundamentals.

HeXun Biosciences , Ltd.'s other current assets is $16M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.